VISN 5 MIRECC - General Publications 2011 - MIRECC / CoE
Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

MIRECC / CoE

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
 

VISN 5 MIRECC - General Publications 2011

 

About Us • Clinical • Education • Research
VISN 5 MIRECC home

 

Brown, C.H., Bennett, M.E., Li, L., & Bellack, A.S. (2011). Predictors of initiation and engagement in substance abuse treatment among individuals with co-occurring serious mental illness and substance use disorders. Addictive Behaviors, 36(5), 439-437.

Brown, C.H., Medoff, D., Dickerson, F.B., Kreyenbuhl, J.A., Goldberg, R.W., Fang, L., & Dixon, L. (2011). Glucose control over time among type 2 diabetes patients with and without serious mental illness. Journal of Nervous and Mental Disease, 199(11), 899-902.

Buchanan, R.W., Keefe, R.S., Lieberman, J.A., Barch, D.M., Csernansky, J.G., Goff, D.C., Gold, J.M., Green, M.F., Jarskog, L.F., Javitt, D.C., Kimhy, D., Kraus, M.S., McEvoy, J.P., Mesholam Gately, R.I., Seidman, L.J., Ball, M.P., McMahon, R.P., Kern, R.S., Robinson, J., & Marder, S.R. (2011). A randomized clinical trial of MK -0777 for the treatment of cognitive impairments in people with schizophrenia. Biological Psychiatry, 69(5), 442-449.

Carpenter, W.T. (2011). Criticism of the DSM-V risk syndrome: A rebuttal. Cognitive Neuropsychiatry, 16(2), 101-106.

Carpenter, W.T. (2011). The facts of schizophrenia: A personal commentary. Schizophrenia Research, 128(1-3), 3-4.

Carpenter, W.T. (2011). One hundred years. Schizophrenia Bulletin, 37(3), 443-444.

Carpenter, W.T., & van Os, J. (2011). Should attenuated psychosis syndrome be a DSM-5 diagnosis? American Journal of Psychiatry, 168, 460-463.

Carter, C.S., Barch, D.M., Bullmore, E., Breiling, J., Buchanan, R.W., Butler, P., Cohen, J.D., Geyer, M., Gollub, R., Green, M.F., Jaeger, J., Krystal, J.H., Moore, H., Nuechterlein, K., Robbins, T., Silverstein, S., Smith, E.E., Strauss, M., & Wykes, T. (2011). Cognitive neuroscience treatment research to improve cognition in schizophrenia II: Developing imaging biomarkers to enhance treatment development for schizophrenia and related disorders. Biological Psychiatry, 70(1), 7-12.

Couture, S.M., Blanchard, J.J., & Bennett, M.E. (2011). Negative expectancy appraisals and defeatist performance beliefs and negative symptoms of schizophrenia. Psychiatry Research, 189(1), 43-48.

Day, H.R., Morgan, D.J., Young, A., Himelhoch, S., & Perencevich, E.N. (2011). Association between depression and contact precautions in veterans at hospital admission. American Journal of Infection Control, 39(2), 163-5.

Day, H.R., Perencevich, E.N., Harris, A.D., Gruber-Baldini, A.L., Himelhoch, S., Brown, C.H., Dotter, E., & Morgan, D.J. (2011). The association between contact precautions and delirium at a tertiary care center. Infection Control and Hospital Epidemiology, 33, 34-9.

Day, H.R., Perencevich, E.N., Harris, A.D., Himelhoch, S.S., Brown, C.H., Gruber-Baldini, A.L., Dotter, E., & Morgan, D.J. (2011). Do contact precautions cause depression? A two-year study at a tertiary care medical centre. Journal of Hospital Infection, 79(2), 103-107.

Dickerson, F., Bennett, M., Dixon, L., Burke, E., Vaughan, C., Delahanty, J., & DiClemente, C. (2011). Smoking cessation in persons with serious mental illness: The experience of successful quitters. Psychiatric Rehabilitation Journal, 34(4), 311-316.

DiClemente, C.C., Delahanty, J.C., Kofeldt, M.G., Dixon, L., Goldberg, R., & Lucksted, A. (2011). Stage movement following a 5A’s intervention in tobacco dependent individuals with serious mental illness (SMI). Addictive Behavior, 36(3), 261-264.

Divilbiss, M., McCleery, A., Aakre, J.M., Seghers, J.P., Schumann, E.B., & Docherty, N.M. (2011). Reality monitoring and its association with social functioning in schizophrenia. Psychiatry Research 186(1), 1-4.

Dixon, L., Lewis-Fernandez, R., Goldman, H.H., Interian, A., Michaels, A., & Kiley, M.C. (2011). Adherence disparities in mental health: Opportunities and challenges. Journal of Nervous and Mental Disease, 199(10), 815-820.

Dixon, L.B., Lucksted, A., Medoff, D., Burland, J., Stewart, B., Lehman, A., Fang, L., Sturm, V., Brown, C., & Murray-Swank, A. (2011). Outcomes of a randomized study of a peer-taught Family-To-Family education program for mental illness. Psychiatric Services, 62, 591-597.

Docherty, N.M., St-Hilaire, A., Aakre, J.M., Seghers, J.P., McCleery, A., & Divilbiss, M. (2011). Anxiety interacts with expressed emotion criticism in the prediction of psychotic symptom exacerbation. Schizophrenia Bulletin, 37(3), 611-618.

Drapalski, A. L., Bennett, M., & Bellack, A. S. (2011). Gender differences in substance use, consequences, motivation to change, and treatment seeking in people with serious mental illness. Substance Use & Misuse, 46(6), 808-818.

Drapalski, A.L., & Dixon, L.B. (2011). Programmes to support family members and carers. In G. Thornicroft, G. Szmukler, K. Mueser, & R. Drake (Eds.), Oxford Textbook of Community Mental Health, 2nd Edition. Oxford: Oxford University Press.

Ehrenreich, B., Righter, B., Rocke, D., Dixon, L., & Himelhoch, S. (2011). Are mobile phones and handheld computers being used to enhance delivery of psychiatric treatment? A systematic review. Journal of Nervous and Mental Disease, 199 (11), 886-891.

Essock, S.M., Schooler, N.R., Stroup, T.S., McEvoy, J.P., Rojas, I., Jackson, C., Covell, N.H., Schizophrenia Trials Network. (2011). Effectiveness of switching from polypharmacy to monotherapy. American Journal of Psychiatry, 168(7), 702-708.

Fischer, BA, & Buchanan, RW. (2011). Schizophrenia: Clinical manifestations, assessment, diagnosis, and course. In: D.S. Basow (Ed.), UpToDate. Waltham, MA: UpToDate.

Forbes, C.B., Blanchard, J.J., Bennett, M., Horan, W.P., Kring, A., & Gur, R. (2010). Initial development and preliminary validation of a new negative symptom measure: The Clinical Assessment Interview for Negative Symptoms. Schizophrenia Research, 124, 36-42.

Green, M.F., Schooler, N.R., Kern, R.S., Frese, F.J., Granberry, W., Harvey, P.D., Karson, C.N., Peters, N., Stewart, M., Seidman, L.J., Sonnenberg, J., Stone, W.S., Walling, D., Stover, E., & Marder, SR. (2011). Evaluation of co-Primary measures for clinical trials of cognition enhancement in schizophrenia. American Journal of Psychiatry, 168, 400-407.

Himelhoch, S., Goldberg, R., Calmes, C., Medoff, D., Slade, E., Gallucci, G., Dixon, L., & Rosenberg, S. (2011). Screening for and prevalence of HIV and hepatitis C among an outpatient urban sample of people with serious mental illness and co occurring substance abuse. Journal of Community Psychology, 39(2), 231-239.

Himelhoch, S., Mohr, D., Weber, E., Maxfield, J., Clayton, S., Medoff, D., & Dixon, L. (2011). Feasibility of telephone based cognitive behavioral therapy targeting major depression among urban dwelling African-Americans with co-occurring HIV. Psychology, Health & Medicine, 16(2), 156-165.

Hong, L.E., Schroeder, M., Ross, T.J., Buchholz, B., Salmeron, B.J., Wonodi, I., Thaker, G.K., & Stein E.A. (2011). Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. Schizophrenia Bulletin, 37(2), 416-25.

Hong, L.E., Thaker, G.K., McMahon, R.P., Summerfelt, A., Rachbeisel, J., Fuller, R.L., Wonodi, I., Buchanan, R.W., Myers, C., Heishman, S.J., Yang, J, & Nye, A. (2011). Effects of moderate-dose treatment with varenicline on neuro-biological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder. Archives of General Psychiatry, 68(12), 1195-1206.

Hong, L.E., Yang, X., Wonodi, I., Hodgkinson, C.A., Goldman, D., Stine, O.C., Stein, E.S., & Thaker, G.K. (2011). A CHRNA5 allele related to nicotine addiction and schizophrenia. Genes, Brain, & Behavior, 10(5), 530-535.

Hou, Y.Z., Xiang, Y.T., Yan, F., Ungvari, G.S., Dickerson, F., Chiu, H.F.K., Lai, K.Y.C., Lee, E.H.M., Li, W.Y., Li, W.X., Zhu, Y.L., & Dixon, L.B. (2011). Cigarette smoking in community-dwelling patients with schizophrenia in China. Journal of Psychiatric Research, 45 (12), 1551-1556.

Keshavan, M.S., Morris, D.W., Sweeney, J.A., Pearlson, G., Thaker, G., Seidman, L.J., Eack, S.M., & Tamminga, C. (2011). A dimensional approach to the psychosis spectrum between bipolar disorder and schizophrenia: The Schizo-Bipolar scale. Schizophrenia Research, 133 (1-3), 250-254.

Kirkpatrick, B., Strauss, G., Nguyen, L., Fischer, B.A., Daniel, D.G., Cienfuegos, A., Marder, S.R. (2011). The Brief Negative Symptom Scale: Psychometric properties. Schizophrenia Bulletin, 37(2), 300-305.

Kreyenbuhl, J., Leith, J, Medoff, D.R., Fang, L., Dickerson, F.B., Brown, C., Goldberg, R.W., Potts, W., & Dixon, L.B. (2011). A comparison of adherence to hypoglycemic medications between type 2 diabetes patients with and without serious mental illness. Psychiatry Research, 188, 109-114.

Kreyenbuhl, J., Slade, E.P., Medoff, D.R., Brown, C.H., Ehrenreich, B., Afful, J., & Dixon, L.B. (2011). Time to discontinuation of first- and second-generation antipsychotic medications in the treatment of schizophrenia. Schizophrenia Research, 131(1-3), 127-132.

Lewis, R., Adler, D.A., Dixon, L.B., Goldman, B., Hackman, A.L., Oslin, D.W., Siris, S.G., & Valenstein, M. (2011). The psychiatric note in the era of electronic communication. Journal of Nervous and Mental Disease, 199(4), 212-13.

Lucksted, A., Drapalski, A.L., Calmes, C., Forbes, C., DeForge, B., & Boyd, J. (2011). Ending Self Stigma: Pilot evaluation of a new intervention to reduce internalized stigma among people with serious mental illnesses. Psychiatric Rehabilitation Journal, 35(1), 51-54.

Mann-Wrobel, M., Bennett, M.E., Weiner, E. E., Buchanan, R. W., & Ball, M.P. (2011). Smoking history and motivation to quit in smokers with schizophrenia in a smoking cessation program. Schizophrenia Research, 126(1-3), 277-283.

Nossell, I., Calmes, C., Brown, C., Kreyenbuhl, J., Goldberg, R., Fang, L., & Dixon, L. (2010). Patterns of emergency room use for medical conditions among those with serious mental illness. Psychiatric Services, 61, 1251-1254.

Weiner, E., Buchholz, A., Coffay, A., Liu, F., McMahon, R.P., Buchanan, R.W., & Kelly, D.L. (2011). Varenicline for smoking cessation in people with schizophrenia: A double blind randomized clinical trial. Schizophrenia Research, 129(1),94-95.

Weiner, E., Conley, R.R., Ball, M.P., Feldman, S., Gold, J.M., Kelly, D.L., Wonodi, I., McMahon, R.P., & Buchanan, R.W. (2010). Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine. Neuropsychopharmacology, 35(11), 2274-83.

Wonodi, I., Gopinath, H.V., Liu, J., Adami, H., Hong, L.E., Allen-Emerson, R., McMahon, R.P., & Thaker, G.K. (2011). Dipyridomole monotherapy in schizophrenia: Pilot of a novel treatment approach by modulation of purinergic signaling. Psychopharmocology, 218(2), 341-345.

Wonodi, I., Stine, O.C., Sathyasaikumar, K.V., Roberts, R.C., Mitchell, B.D., Hong, L.E., Kajii, Y., Thaker, G.K., & Schwarcz, R. (2011). Down-regulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Archives of General Psychiatry, 68(7), 665-674.

Xiang, Y.T., Wang, C.Y., Si, T.M., Lee, E.H., He, Y.L., Ungvari, G.S., Chiu, H.F., Shinfuku, N., Yang, S.Y., Chong, M.Y., Kua, E.H., Fujii, S., Sim, K., Yong, M.K., Trivedi, J.K., Chung, E.K., Udomratn, P., Chee, K.Y., Sartorius, N., Dixon, L.B., Kreyenbuhl, J.A., & Tan, C.H. (2011). Clozapine use in schizophrenia: Findings of the research on Asia psychotropic prescription (REAP) studies from 2001 to 2009. Australian and New Zealand Journal of Psychiatry, 45(11), 968-975.

Xiang, Y.T., Wang, C.Y., Ungvari, G.S., Kreyenbuhl, J.A., Chiu, H., Lai, K., Edwin Ho Ming Lee, B.O.Q.J., & Dixon, L.B. (2011). Weight changes and their associations with demographic and clinical characteristics in risperidone maintenance treatment in schizophrenia. Pharmacopsychiatry, 44(4), 135-141.

Young, A.S., Niv, N., Chinman, M., Dixon, L., Eisen, S.V., Fischer, E.P., Smith, J., Valenstein, M., Marder, S.R., & Owen, R.R. (2011). Routine outcomes monitoring to support improving care for schizophrenia: Report from the VA Mental Health QUERI. Community Mental Health Journal, 47(2), 123-35.